Tower Research Capital (TRC)’s Verona Pharma VRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-137
Closed -$14.6K 5644
2025
Q3
$14.6K Buy
137
+65
+90% +$6.79K ﹤0.01% 3589
2025
Q2
$6.81K Sell
72
-66
-48% -$4.89K ﹤0.01% 4090
2025
Q1
$8.76K Sell
138
-770
-85% -$46.1K ﹤0.01% 3855
2024
Q4
$42.2K Sell
908
-52
-5% -$1.95K ﹤0.01% 2663
2024
Q3
$27.6K Sell
960
-206
-18% -$5.07K ﹤0.01% 3060
2024
Q2
$16.9K Buy
1,166
+466
+67% +$6.8K ﹤0.01% 3851
2024
Q1
$11.3K Sell
700
-3,795
-84% -$65.6K ﹤0.01% 3585
2023
Q4
$89.4K Buy
4,495
+4,067
+950% +$60K ﹤0.01% 2730
2023
Q3
$6.98K Sell
428
-2,710
-86% -$52.2K ﹤0.01% 4528
2023
Q2
$66.3K Sell
3,138
-1,396
-31% -$29.8K ﹤0.01% 2349
2023
Q1
$91K Buy
4,534
+3,803
+520% +$82.1K ﹤0.01% 1961
2022
Q4
$19K Buy
731
+178
+32% +$2.37K ﹤0.01% 3192
2022
Q3
$6K Sell
553
-1,573
-74% -$13.3K ﹤0.01% 5066
2022
Q2
$8K Buy
2,126
+1,095
+106% +$4.68K ﹤0.01% 4716
2022
Q1
$5K Buy
1,031
+698
+210% +$4.06K ﹤0.01% 5116
2021
Q4
$2K Sell
333
-1,444
-81% -$7.38K ﹤0.01% 5678
2021
Q3
$10K Buy
1,777
+412
+30% +$2.4K ﹤0.01% 4346
2021
Q2
$9K Buy
+1,365
New +$9.46K ﹤0.01% 4452
2020
Q3
Sell
-200
Closed -$1K 5127
2020
Q2
$1K Buy
+200
New +$926 ﹤0.01% 4649
2019
Q3
Sell
-262
Closed -$1K 4542
2019
Q2
$1K Sell
262
-104
-28% -$634 ﹤0.01% 3496
2019
Q1
$2K Sell
366
-76
-17% -$495 ﹤0.01% 3466
2018
Q4
$4K Buy
442
+187
+73% +$2.12K ﹤0.01% 3075
2018
Q3
$3K Hold
255
﹤0.01% 3345
2018
Q2
$3K Sell
255
-215
-46% -$3.62K ﹤0.01% 3260
2018
Q1
$9K Buy
+470
New +$6.79K ﹤0.01% 2510
2017
Q4
Sell
-199
Closed -$3K 4067
2017
Q3
$3K Buy
+199
New +$2.63K ﹤0.01% 3497

Other funds holding VRNA

Tower Research Capital (TRC)'s VRNA Position: Q4 2025 in Review

Tower Research Capital (TRC) sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 137 shares — an estimated $14.6K sold.

Tower Research Capital (TRC) first reported a position in VRNA in Q3 2017 and held it in 26 quarters. The position peaked at $91K in Q1 2023. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

  • Tower Research Capital (TRC) reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 137 Verona Pharma shares in Q4 2025, an estimated $14.6K.
  • Tower Research Capital (TRC) first reported a position in Verona Pharma in Q3 2017 and held it in 26 quarters.
  • Tower Research Capital (TRC)'s Verona Pharma position peaked at $91K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.